ClinicalTrials.gg
CompletedNCT06050226Updated Jul 30, 2025

A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 2 interventional study of MY008211A tablets in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Wuhan Createrna Science and Technology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Wuhan Createrna Science and Technology Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Enrollment
29th of 47
34 · median 40
Started
2023
with 5 others
Phase 2
13 of 51
4 open now
Registered
17th of 51
by date
Lead sponsor
8 of 51
Wuhan Createrna Science and Technology Co., Ltd

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 29th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2023, is one of 13 in phase 2, and was the 17th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH , showing signs of active hemolysis, in China.

Read the detailed description

The purpose of this study is to determine whether MY008211A is efficacious and safe for the treatment of PNH patients who are naive to complement inhibitor therapy, including anti-C5 antibody.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants ≥ 18 years of age, ≥18 kg/m2,with a diagnosis of PNH confirmed by laboratory tests, according to the PNH diagnostic criteria in the Chinese Guidelines for the Diagnosis and Treatment of Rare Diseases (2019 edition) , and flow cytometry with clone size ≥ 10%.
  • Mean level \<100 g/L.
  • LDH > 1.5 x (ULN)
  • Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given.

Exclusion criteria

Exclusion Criteria:

  • Patients with reticulocytes \<100x10\^9/L; \<30x10\^9/L; neutrophils \<0.5x10\^9/L.
  • Were using a complement inhibitor before the first administration of MY008211A tablets or had discontinued a previous complement inhibitor for less than five half-lives or 120 days, whichever was the longest.
  • History of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus.
  • Known or suspected hereditary complement deficiency
  • Previous bone marrow or hematopoietic stem cell transplantation.
  • Previous splenectomy.
  • A history of within 5 years before screening, except cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Arm1:low MY008211A dose

    Participants will receive low MY008211A dose orally b.i.d

    Drug: MY008211A tablets

  • Experimental
    Arm2:high MY008211A dose

    Participants will receive high MY008211A dose orally b.i.d

    Drug: MY008211A tablets

Interventions

  • The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.

    Also known as: MY008211A

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving a sustained increase in hemoglobin levels of ≥ 20 g/L in the absence of red blood cell transfusion.

    Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ≥ 20 g/L assessed , in the absence of red blood cell transfusions

    Time frame: up to 84 days

Secondary outcomes

  1. Proportion of participants achieving sustained hemoglobin levels ≥ 120 g/L in the absence of red blood cell transfusions.

    Proportion of participants achieving sustained hemoglobin levels ≥ 120 g/L in absence of red blood cell transfusion

    Time frame: up to 84 days

  2. Change from baseline in hemoglobin concentration.

    Change from baseline in hemoglobin concentration (g/L) in absence of red blood cell transfusion

    Time frame: up to 84 days

  3. Change from baseline in serum LDH levels.

    Change from baseline in serum LDH levels (U/L)

    Time frame: up to 84 days

  4. Change from baseline in Reticulocyte count.

    Change from baseline in Reticulocyte count (×10\^9/L)

    Time frame: up to 84 days

  5. Changes from baseline in transfusion volume.

    The average number of red blood cells transfused per week

    Time frame: up to 84 days

  6. Change in the level of PNH red cell clones.

    Change from baseline in the level of PNH red cell clones.

    Time frame: up to 84 days

  7. Occurrences of AEs occurring between Day 1 and Day 84.

    Adverse Events (AEs)

    Time frame: up to 84 days

Other outcomes

  1. Changes from baseline in alternative complement pathway activity.

    Alternative complement pathway activity measured by the WIESLAB® kit.

    Time frame: up to 84 days

  2. Change from baseline in plasma levels of the Bb fragment.

    Bb fragment cleaved by factor B of complement.

    Time frame: up to 84 days

  3. Maximum Plasma Concentration (Cmax) Of MY008211A tablets

    PK parameters

    Time frame: up to 84 days

  4. Area Under The Concentration Versus Time Curve (AUC) Of MY008211A

    PK parameters

    Time frame: up to 84 days

07

Study locations

1 site
  • Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Tianjin, Tianjin Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Apr 2024, 9 months.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 9 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 22, 2023
StartActual
Jul 6, 2023
Primary completionActual
Apr 30, 2024
CompletionActual
Nov 28, 2024
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06050226
Lead sponsor
Wuhan Createrna Science and Technology Co., Ltd
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Jul 6, 2023
Primary completion
Apr 30, 2024
Completion
Nov 28, 2024
Last update
Jul 30, 2025

Study contacts

Fengkui Zhang, Ph.D
principal investigator · Blood Disease Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lanoracopan

Start the discussion